v3.25.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:      
Net loss $ (280,885) $ (666,704) $ (311,656)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 14,316 23,227 32,071
Amortization and impairment of internal-use software 9,036 6,255 4,427
Stock-based compensation expense 62,027 120,209 116,017
Impairment of long-lived assets 60,398 0 10,126
Goodwill impairment 0 351,744 0
(Gain) loss on disposal of property and equipment (369) (25) 61
Loss on disposition of Lemonaid Health Limited 0 2,026 0
Reorganization items 1,415 0 0
Other operating activities 0 (504) 16
Changes in operating assets and liabilities:      
Accounts receivable, net 1,972 (1,427) 1,483
Inventories (3,093) (2,218) 542
Deferred cost of revenue (381) 584 2,325
Prepaid expenses and other current assets 1,160 (1,231) 6,653
Operating lease right-of-use assets 6,642 7,185 7,393
Other assets (3,496) 1,152 (429)
Accounts payable (includes related party amounts of $(3,809), $623 and $(9,381), respectively) (5,769) (996) (24,573)
Accrued expenses and other current liabilities (includes related party amounts of $(4,497), $(1,986) and $2,966, respectively) 666 (7,104) 2,671
Deferred revenue (includes related party amounts of $(20,087), $9,246 and $2,572, respectively) (25,480) 12,307 (418)
Operating lease liabilities (8,087) (8,790) (8,934)
Other liabilities 343 (9) (3,165)
Net cash used in operating activities (169,585) (164,319) (165,390)
Cash flows from investing activities:      
Purchases of property and equipment (869) (1,129) (4,048)
Proceeds from sale of property and equipment 3,158 30 5
Capitalized internal-use software costs (5,992) (8,527) (7,262)
Net cash used in investing activities (3,703) (9,626) (11,305)
Cash flows from financing activities:      
Proceeds from exercise of stock options 58 909 4,203
Proceeds from issuance of common stock under employee stock purchase plan 613 3,262 6,464
Payments for taxes related to net share settlement of equity awards (150) (230) (197)
Payments of deferred offering costs 0 (357) (693)
Payments of debtor in possession financing costs (reorganization items) (800) 0 0
Net cash (used in) provided by financing activities (279) 3,584 9,777
Effect of exchange rates on cash and cash equivalents 0 0 385
Net decrease in cash, cash equivalents and restricted cash (173,567) (170,361) (166,533)
Cash, cash equivalents and restricted cash — beginning of period 224,861 395,222 561,755
Cash, cash equivalents and restricted cash — end of period 51,294 224,861 395,222
Supplemental disclosures of non-cash investing and financing activities:      
Purchases of property and equipment included in accounts payable and accrued expenses 0 97 473
Stock-based compensation capitalized for internal-use software costs 1,924 3,606 3,191
Unpaid settlement of employee equity awards included in accrued expenses 5,323 0 0
Deferred offering costs during the period included in accounts payable and accrued expenses 0 1 45
Reconciliation of cash, cash equivalents, and restricted cash within the consolidated balance sheets to the amounts shown in the consolidated statements of cash flows above:      
Cash and cash equivalents 38,248 216,488 386,849
Restricted cash, current 7,746 1,399 1,399
Restricted cash, noncurrent 5,300 6,974 6,974
Total cash, cash equivalents and restricted cash $ 51,294 $ 224,861 $ 395,222